The European Commission has cleared AstraZeneca’s (AZ) proposed acquisition of rare disease specialist Alexion, initially announced in December 2020.
Last year, AZ revealed its plans to acquire Alexion for approximately US$39 billion, in a bid to establish a specialist rare disease pipeline in the process.
Alexion’s portfolio of rare disease medicationss includes Soliris (eculizumab), a first-in-class anti-complement component 5 (C5) monoclonal antibody, and Ultomiris (ravulizumab), a second-generation C5 monoclonal antibody.
In a statement, AZ stated the EC clearance marks an “important step” towards the completion of the proposed acquisition.
The proposed acquisition has already received complete clearances from regulatory authorities in the US, Japan, and other countries globally. However, clearance in the UK is still pending and remains a requirement to complete the deal.
“We are pleased to have secured clearance from the European Commission for the proposed acquisition of Alexion, a pioneer in the discovery and development of medicines for rare diseases,” said Marc Dunoyer, executive director and chief financial officer of AZ.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI